Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 15/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697315 | 0.88 | OPRM1 (0.75) | OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL4701083 | 0.84 | OPRM1 (0.70) | OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL4702161 | 0.83 | OPRM1 (0.60) | OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL4699192 | 0.82 | OPRM1 (0.50) | OPRM1OPRD1OPRK1KCNH2CCR1 | |
| SCHEMBL4697321 | 0.77 | OPRM1 (0.54) | OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL4697748 | 0.77 | OPRM1 (0.71) | OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL4697594 | 0.76 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL4700489 | 0.76 | OPRM1 (0.86) | OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL5703381 | 0.74 | OPRM1 (0.82) | OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL4697637 | 0.70 | OPRM1 (0.71) | OPRM1OPRD1OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1440059-A1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2004-07-28 | — | — | EP | claimed |
| US-20030087898-A1 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. | 2003-05-08 | — | — | US | claimed |
| WO-2003035622-A1 | 3-AZABICYCLO (3.1.0) HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-05-01 | — | — | WO | claimed |
| EP-1440059-B1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070054950-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | PFIZER INC. | 2007-03-08 | — | — | US | disclosed |
| US-7153976-B2 | Purification process for an azabicyclo[3.1.0]hexane compound | PFIZER INC. (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1678136-A1 | PROCESS FOR PREPARING AN AZABICYCLO[3.1.0]HEXANE COMPOUND | Pfizer Products Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-7049335-B2 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20050171178-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| WO-2005033080-A1 | PROCESS FOR PREPARING AN AZABICYCLO[3.1.0]HEXANE COMPOUND | PFIZER PRODUCTS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050075387-A1 | Process for preparing an azabicyclo[3.1.0] hexane compound | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| EP-1440059-A1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20030087898-A1 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2003035622-A1 | 3-AZABICYCLO (3.1.0) HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087898-A1 | 3-azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 1/4885OPRK1 3/4885 |
| US-20050171178-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 1/4885OPRK1 3/4885 |
| US-20070054950-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 1/4885OPRK1 3/4885 |
| US-20050075387-A1 | Process for preparing an azabicyclo[3.1.0] hexane compound | AZI2, CYP1B1, CYP4B1 | OPRM1 2847/4885OPRD1 1930/4885OPRK1 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.